Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2022 | Developing therapeutics to rebuild the blood-brain barrier

Richard Daneman, PhD, University of California San Diego, San Diego, CA, comments on the promise of the blood-brain barrier as a therapeutic target in neurological disease. Blood-brain barrier dysfunction and breakdown is an early symptom in numerous neurological diseases, thought to trigger subsequent neuronal dysfunction and ultimately, neurodegeneration. Many groups are looking to develop therapeutics to rebuild the blood-brain barrier, or prevent its breakdown, in order to tackle disease progression. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.